Drug Trial Radar · NCT02203032
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Last checked: Nov 20, 2026Latest source record: Sep 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
872
Actual
Start
Oct 7, 2014
Primary completion
Dec 25, 2015
Study completion May 24, 2016
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jul 29, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash) who had inadequate response to ustekinumab.
Conditions
- Psoriasis
Interventions
UstekinumabDrug
45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
GuselkumabDrug
100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
Placebo for ustekinumabDrug
Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
Placebo for guselkumabDrug
Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40Time frame: Week 28 through Week 40
Locations
85 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Bakersfield, California
Site not named
Los Angeles, California
Site not named
Santa Monica, California
Site not named
Coral Gables, Florida
Site not named
Ocala, Florida
Site not named
Alpharetta, Georgia
Site not named
Atlanta, Georgia
Site not named
Arlington Heights, Illinois
Site not named
Chicago, Illinois
Site not named
Skokie, Illinois
Site not named
Indianapolis, Indiana
Site not named
Plainfield, Indiana
Site not named
Louisville, Kentucky
Site not named
Boston, Massachusetts
Site not named
Troy, Michigan
Site not named
Buffalo, New York
Site not named
New York, New York
Site not named
Portland, Oregon
Site not named
Pittsburgh, Pennsylvania
Site not named
Johnston, Rhode Island
Site not named
Nashville, Tennessee
Site not named
Arlington, Texas
Site not named
Austin, Texas
Site not named
Dallas, Texas
Site not named
San Antonio, Texas
Site not named
Webster, Texas
Site not named
Norfolk, Virginia
Site not named
Spokane, Washington
Site not named
Fremantle, Australia
Site not named
Victoria Park, Australia
Site not named
Woden, Australia
Site not named
Woolloongabba, Australia
Site not named
Surrey, British Columbia, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Moncton, New Brunswick, Canada
Site not named
Halifax, Nova Scotia, Canada
Site not named
Ajax, Ontario, Canada
Site not named
Richmond Hill, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.